Concord Biotech’s initial public offering (IPO) generated substantial interest from investors, with the public issue being subscribed to 24.87 times.
According to topsharebrokers.com, the Concord Biotech IPO GMP today is 121 per share. According to market experts, Concord Biotech shares are currently selling in the grey market at a premium of 121, which is 4 less than the GMP of 125.
According to market observers, Concord Biotech IPO GMP today is 121, which suggests the grey market expects Concord Biotech IPO listing price to be approximately 862 (741 + 121), which is around 16.33% higher than Concord Biotech IPO pricing band specified at 705 to 741 per equity share.
The Concord Biotech IPO was subscribed to 24.87 times by the end of the bidding procedure on the last day.
Concord Biotech IPO’s retail category was booked 3.78 times, while the Non-Institutional Investors (NII) category was subscribed 16.99 times. The quota for Qualified Institutional Investors was booked 67.67 times.
Employees bid 24.48 times the allotted quota. The company had reserved 10,000 equity shares for its employees in the IPO and is offering them shares at a discount of ₹70 per share to the final offer price.